熱門資訊> 正文

Allogene Therapeutics任命Zachary Roberts为计划中的继任者

2026-05-29 05:29

Allogene Therapeutics, Inc.(ALLO) 0

Allogene Therapeutics (ALLO) said on Thursday that CEO David Chang will step down effective June 30 after eight years leading the company and will remain on its board of directors.
The company named Zachary Roberts, currently executive vice president of research and development and chief medical officer, as president and CEO, effective July 1.
Roberts will also join the board.

More on Allogene Therapeutics

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M
Allogene Therapeutics GAAP EPS of -$0.18 beats by $0.01

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。